原位和循环中的溶质载体家族3成员2（SLC3A2）均可作为人肺鳞状细胞癌和肺腺癌的预后标志物。

Both In Situ and Circulating SLC3A2 Could Be Used as Prognostic Markers for Human Lung Squamous Cell Carcinoma and Lung Adenocarcinoma.

作者信息

Liu Dahua, An Min, Wen Guimin, Xing Yanan, Xia Pu

机构信息

Biological Anthropology Institute, College of Basic Medical Science, Jinzhou Medical University, Jinzhou 121001, China.

Department of Cardiology, Jinzhou Central Hospital, Jinzhou 121001, China.

出版信息

Cancers (Basel). 2022 Oct 22;14(21):5191. doi: 10.3390/cancers14215191.

DOI:10.3390/cancers14215191

PMID:36358610

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9658420/

Abstract

SLC3A2, the heavy chain of the CD98 protein, is highly expressed in many cancers, including lung cancer. It can regulate the proliferation and the metastasis of cancer cells via the integrin signaling pathway. Liquid biopsy is a novel method for tumor diagnosis. The diagnostic or prognostic roles of serum SLC3A2 in lung cancer are still not clear. In this study, we analyzed SLC3A2 mRNA levels in human lung squamous cell carcinoma (LUSC) and lung adenocarcinoma (LUAD) using the TCGA database and serum SLC3A2 protein levels using ELISA. We confirmed high SLC3A2 levels in both the serum and tissue of LUAD and LUSC patients. Both serum and tissue SLC3A2 could be used as prognostic markers for overall LUAD and subgroups of LUSC patients. SLC3A2 induced tumorigenesis via the MEK/ERK signaling pathway in LUAD and LUSC cells.

摘要

溶质载体家族3成员2（SLC3A2）是CD98蛋白的重链，在包括肺癌在内的多种癌症中高表达。它可通过整合素信号通路调节癌细胞的增殖和转移。液体活检是一种新型肿瘤诊断方法。血清SLC3A2在肺癌中的诊断或预后作用仍不明确。在本研究中，我们使用TCGA数据库分析了人肺鳞状细胞癌（LUSC）和肺腺癌（LUAD）中SLC3A2 mRNA水平，并使用酶联免疫吸附测定（ELISA）分析了血清SLC3A2蛋白水平。我们证实LUAD和LUSC患者的血清和组织中SLC3A2水平均较高。血清和组织中的SLC3A2均可作为总体LUAD和LUSC患者亚组的预后标志物。SLC3A2通过MEK/ERK信号通路在LUAD和LUSC细胞中诱导肿瘤发生。